In Re: Niaspan Antitrust Litigation

  1. June 05, 2023

    3rd Circ. Rejects Rehearing Bid From Niaspan Buyers

    The Third Circuit on Monday refused a rehearing bid from Niaspan buyers accusing AbbVie Inc. and Teva Pharmaceuticals Ltd. of scheming to delay a generic version of the cholesterol drug, after an appeals panel found the lower court was right not to certify a class of insurance plans and other end payors.

  2. May 09, 2023

    Niaspan Buyers Ask 3rd Circ. For Rehearing On Class Cert.

    Niaspan buyers told the Third Circuit that an appeals panel was wrong to reject their class certification bid based on the number of prescriptions at issue in their case accusing AbbVie Inc. of paying to delay a generic version of the cholesterol drug.

  3. May 05, 2023

    3rd Circ. Upholds Class Cert. Denial In Niaspan MDL

    The Third Circuit has upheld a Pennsylvania federal court's denial of class certification to a group of union insurance plans that claimed AbbVie Inc. paid to delay a generic version of the cholesterol drug Niaspan.

  4. February 24, 2023

    Teva, AbbVie Tell 3rd Circ. New Precedent Won't Help Buyers

    AbbVie and Teva Pharmaceuticals pushed back Thursday after buyers of the cholesterol drug Niaspan asked the Third Circuit to consider one of its 2022 opinions before deciding whether to deny them class certification in a suit accusing the pharma companies of a pay-for-delay deal, saying the opinion actually supports denying certification.

  5. February 22, 2023

    3rd Circ. Asked To Look At New Precedent In Class Cert. Fight

    Niaspan buyers want the Third Circuit to take a look at an opinion it handed down last year before deciding whether to overturn a decision denying them class certification in their litigation accusing AbbVie and Teva Pharmaceuticals of costing them money through an illegal pay-for-delay deal.

  6. September 06, 2022

    3rd Circ. Panel Questions Niaspan Buyers' Class Data

    A Third Circuit panel on Tuesday raised a number of questions for Niaspan buyers about the data supporting their bid for class status in a case accusing AbbVie and Teva Pharmaceuticals of delaying generic forms of the cholesterol drug.

  7. September 02, 2022

    3rd Circ. Preview: J&J Unit, Pipeline Fights On Sept. Docket

    As the Third Circuit heads back to school this month, panels will be studying cancer patients' attempts to dismiss a J&J talc liability unit's bankruptcy as a bad-faith maneuver and fights by an order of nuns and a utility infrastructure company over natural gas pipelines.

  8. September 01, 2022

    IP Forecast: Patent Biz To Fight For Its Right To Keep Suing

    Patent-licensing business Uniloc heads to the Federal Circuit next week to argue for the revival of its suits against Google and others, contending that a deal Uniloc cut with a litigation funder did not undercut its legal standing to assert a vast trove of patents. Here's a look at that case — plus all the other major intellectual property matters on deck in the coming week.

  9. March 21, 2022

    DC Group Backs Pharma Cos. In Niaspan Pay-For-Delay Case

    The Washington Legal Foundation has thrown its support behind AbbVie and Teva Pharmaceuticals, urging the Third Circuit in an amicus brief to reject an appeal from end-payors seeking class certification in their suit accusing the companies of delaying generic forms of cholesterol drug Niaspan from entering the market.

  10. January 21, 2022

    'Data-Rich' Sources Can ID Niaspan Class, 3rd Circ. Told

    Antitrust advocacy groups want the Third Circuit to reverse a Pennsylvania federal judge's decision refusing to certify a class of end-payors alleging improper pay-for-delay settlements between AbbVie and Teva Pharmaceuticals delaying generic forms of cholesterol drug Niaspan, arguing there's ample data to identify class members.